ACAN and Alzheimer disease: As we observe significant increases in plaque burden in the 8-month 5x ACAN cKO mice, these findings suggest that disease progression-dependent mechanisms (i.e., additional factors or events occurring between 2 and 8 months) may influence the effects of ACAN loss on AD pathology.